HC Wainwright reaffirmed their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.
Aligos Therapeutics Stock Down 7.0 %
ALGS opened at $8.40 on Wednesday. The firm has a market cap of $656.12 million, a PE ratio of -6.56 and a beta of 2.16. The business has a fifty day simple moving average of $10.59 and a 200-day simple moving average of $13.53. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $30.00.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of ($4.00) by $4.75. The business had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same period in the prior year, the business earned ($10.75) earnings per share. On average, equities research analysts anticipate that Aligos Therapeutics will post -8.2 EPS for the current fiscal year.
Institutional Trading of Aligos Therapeutics
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
See Also
- Five stocks we like better than Aligos Therapeutics
- The How And Why of Investing in Oil Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- 10 Best Airline Stocks to Buy
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Use the MarketBeat Excel Dividend Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.